The Trump administration on Thursday announced a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare ...
Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.
WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it represents a major driver of cardiovascular morbidity, mortality, and ...
Thierry André and colleagues recently reported that nivolumab–ipilimumab provided an impressive absolute progression-free survival benefit at 36 months, which was 17% compared with nivolumab ...
Presented by the Coalition to Strengthen America’s Healthcare — State Medicaid programs that choose to participate in the model will be able to purchase drugs included in the pilot at prices ...
CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for ...
Amylin is a peptide co-secreted with insulin in response to food intake. It controls gastric emptying, inhibits glucagon secretion, and promotes satiety. Several amylin receptor agonists are in ...
Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.
US President Donald Trump announced deals Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback